Maraviroc (Selzentry, Celsentri)
Other Medications · Approved since 2007
Description
Maraviroc is a CCR5 antagonist that blocks the C-C chemokine receptor type 5, originally developed and approved for HIV treatment. In colorectal cancer, maraviroc is being combined with PD-1 inhibitors specifically for microsatellite stable (MSS) metastatic colorectal cancer. This combination approach targets the CCR5 pathway to potentially enhance immune system activation in tumors that typically do not respond well to immunotherapy alone.
Mechanism of Action
Maraviroc selectively binds to and blocks the CCR5 co-receptor on immune cells, preventing CCL5 (RANTES) and other chemokines from binding. By inhibiting CCR5 signaling, maraviroc may reduce immunosuppressive signals in the tumor microenvironment and enhance T-cell infiltration, potentially making microsatellite stable colorectal cancers more responsive to checkpoint inhibition.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Selzentry, Celsentri |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2007 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.